Nature's Sunshine Products, Inc. · NASDAQ:NATR

Nature's Sunshine Products — B. Riley & Co. Investor Conference 2016

20 slides from Nature's Sunshine Products's conference presentation, Sep 13, 2016

  1. Slide 1: Strictly Company Confidential Proprietary Information

    Strictly Company Confidential 1 Proprietary Information

  2. Slide 2: B. Riley & Co. Investor Conference

    B. Riley & Co. Investor Conference September 13, 2016 2

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements regarding the Company’s future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, s

  4. Slide 4: Overview of Nature's Sunshine Products

    Overview of Nature’s Sunshine Products • Global natural health and wellness company that manufactures, markets and distributes 2,700 SKUs through the direct selling and retail channels, utilizing two distinct brands: & • Rich 44 year history; first U.S. company to encapsulate herbs in 1972 • Global

  5. Slide 5: Diversified Revenue Mix

    Diversified Revenue Mix Revenue by Revenue by Revenue by Business Unit Geography Product NSP Russia, China and Central & Weight Personal Care China & New Central and New South Management 4% Markets Eastern Markets America 8% 4% Europe 4% 8% 7% Immune 8% Europe General 14% NSP North Health Synergy Am

  6. Slide 6: Turnaround Story Poised for Growth

    Turnaround Story Poised for Growth 1972 • 44 year history built on strong foundational strengths: (1) commitment to world-class quality; (2) customer service; and (3) integrity – Highest quality self-manufactured products in company-owned facility – Developed and retained stable, large Distributor a

  7. Slide 7: Strong Science Capabilities

    Strong Science Capabilities Systems Phytochemicals Discovery Delivery Clinical • Provides strong competitive advantage that can be leveraged to enter new channels • 8 patents in past 3 years, including ProArgi-9+, CardioxLDL™, AnxiousLess™ and the IN.FORM™ program • Chief Scientific Officer, Dr. Mat

  8. Slide 8: State-of-the-Art Manufacturing Capabilities

    State-of-the-Art Manufacturing Capabilities • 270,000 sq. ft. manufacturing facility built to pharmaceutical standards – Currently operating at 60% capacity – In-house manufacturing of tablets, capsules, liquids, powders and stick pack products enhances speed to market – Continue to develop best-in-

  9. Slide 9: Global Direct Selling Market

    Global Direct Selling Market ($ in Billions) The Direct Selling market is growing, fueled by China $180 $160 $153 $147 $140 $128 $120 $106 $100 Total CAGR: 8.2% $80 RoW CAGR: 6.3% $60 China CAGR: 24.6% $40 $30 $20 $20 $13 $8 $0 2008 2010 2012 2014 Rest of World China Source: World Federation of Dire

  10. Slide 10: China is a Key Component of our Growth Strategy

    China is a Key Component of our Growth Strategy • China is the 2nd largest Direct Selling Market and the 2nd largest VMS Haerbing Market Changchun • Amway China revenues of $4 B & 29% of the Shenyang China direct selling market Beijing Shijiazhuang • NuSkin China revenues Qingdao were $772 M in 2015

  11. Slide 11: Entering China Through Alliance with Fosun Pharma

    Entering China Through Alliance with Fosun Pharma • Working to obtain direct selling license in China in 2016 – First and only Chinese-American direct selling partnership in China – Combines NATR’s 40+ years of experience with Fosun’s brand recognition – Products ready to be in market • Management t

  12. Slide 12: NSP Americas (52% of Business)

    NSP Americas (52%(1) of Business) • Eight consecutive quarters of net sales growth for NSP United States & Canada • Expanding IN.FORM™ in both North America and Latin America • Launched several new products over the past year: – Patent-pending CardioxLDL™ for cholesterol metabolism support – Re-laun

  13. Slide 13: The IN.FORM Program

    TM The IN.FORM Program • Science-based, clinically studied, patent-pending program that supports metabolic function and lowers metabolic age • Conducted IRB-approved, 2 arm healthy weight management clinical study on healthy individuals: – 56% improvement in weight loss vs. diet alone – 65% improvem

  14. Slide 14: Synergy WorldWide (37% of Business)

    Synergy WorldWide (37%(1) of Business) • Developing the Elite Health System with a single global business and product system – Streamlining focus from multiple product strategies to a single cohesive sales method across all regions – Goal to achieve a unified, science-based product offering geared t

  15. Slide 15: Financial Highlights

    Financial Highlights Net Sales Revenue Adjusted EBITDA (3) $ in Millions $ in Millions $400 $35 $32 $370 $366 $31 $0.5 $29 $3 $6 $350 $325 $30 $1.0 $4 $2.2 $1.3 $108 $300 $128 $5.2 $25 $114 $250 $63 $20 $200 $50 $172 $15 $27 $165 $14 $15 $31.4 $0.6 $48 $37 $6 $32 $27.4 $0.9 $150 $2 $1.6 $57 $63 $22.

  16. Slide 16: Generate Significant Cash Flow

    Generate Significant Cash Flow Self-funded major growth initiatives while returning cash to shareholders • Returned $73 million to shareholders in the past three years through regular quarterly and special dividends – Annual dividend of $0.40 (2.9% yield)(2) • Repurchased $17 million worth of shares

  17. Slide 17: Investment Highlights

    Investment Highlights • Emerging growth turnaround story with implementation of major initiatives underway • Well-positioned globally for growth within Vitamin, Mineral and Supplement category • Entry into China provides opportunity for sustainable long-term growth • Science-based product and progra

  18. Slide 18: Appendix

    Appendix Strictly Company Confidential 18 Proprietary Information

  19. Slide 19: Non-GAAP Measures

    Non-GAAP Measures The Company has included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning Adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations. Management utilizes the

  20. Slide 20: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA (Amounts in thousands) (Unaudited) Year Ended December 31, Six Months Ended June, 30 2013 2014 2015 2015 2016 Net Income from continuing operations $ 17,653 $ 19,757 $ 11,

Nature's Sunshine Products — B. Riley & Co. Investor Conference 2016 on 6ix